R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AIInsilico Medicine

Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement

Auto-immuneCancer

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

BiotechCAR-T

Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers

CancerClinical trial results

Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US

Show More